A Phase 2, Multicentre, Double-Blind, Placebo-Controlled, Dose Escalating Trial of the Safety, Pharmacokinetics, and Biological Activity of 3 Consecutive Daily Doses of Serp-1 When Added to Conventional Therapy in Patients With Acute Coronary Syndromes (Non ST-Elevation Myocardial Infarction and/or Unstable Angina)
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2010
At a glance
- Drugs VT 111 (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions
- 17 Dec 2010 Results were published in Circulation: Cardiovascular Interventions, according to a Viron Therapeutics media release.
- 18 Nov 2009 Secondary endpoint 'Creatine kinase MB isoenzyme level' has been met.
- 18 Nov 2009 Secondary endpoint 'Troponin level' has been met.